321 related articles for article (PubMed ID: 19171786)
1. Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration.
Díaz-Hernández M; Díez-Zaera M; Sánchez-Nogueiro J; Gómez-Villafuertes R; Canals JM; Alberch J; Miras-Portugal MT; Lucas JJ
FASEB J; 2009 Jun; 23(6):1893-906. PubMed ID: 19171786
[TBL] [Abstract][Full Text] [Related]
2. Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice.
Engel T; Gomez-Villafuertes R; Tanaka K; Mesuret G; Sanz-Rodriguez A; Garcia-Huerta P; Miras-Portugal MT; Henshall DC; Diaz-Hernandez M
FASEB J; 2012 Apr; 26(4):1616-28. PubMed ID: 22198387
[TBL] [Abstract][Full Text] [Related]
3. Presynaptic dysfunction in Huntington's disease.
Rozas JL; Gómez-Sánchez L; Tomás-Zapico C; Lucas JJ; Fernández-Chacón R
Biochem Soc Trans; 2010 Apr; 38(2):488-92. PubMed ID: 20298208
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.
Ebert AD; Barber AE; Heins BM; Svendsen CN
Exp Neurol; 2010 Jul; 224(1):155-62. PubMed ID: 20227407
[TBL] [Abstract][Full Text] [Related]
5. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Belfiore L; Ly D; Adhikary SR; Fuller SJ; Varikatt W; Sanderson-Smith ML; Sluyter V; Alexander SI; Sluyter R; Watson D
Clin Exp Immunol; 2017 Oct; 190(1):79-95. PubMed ID: 28665482
[TBL] [Abstract][Full Text] [Related]
6. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease.
Shehadeh J; Fernandes HB; Zeron Mullins MM; Graham RK; Leavitt BR; Hayden MR; Raymond LA
Neurobiol Dis; 2006 Feb; 21(2):392-403. PubMed ID: 16165367
[TBL] [Abstract][Full Text] [Related]
7. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
[TBL] [Abstract][Full Text] [Related]
8. Involvement of P2X7 receptors in the hypoxia-induced death of rat retinal neurons.
Sugiyama T; Oku H; Shibata M; Fukuhara M; Yoshida H; Ikeda T
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3236-43. PubMed ID: 20071682
[TBL] [Abstract][Full Text] [Related]
9. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease.
Fan MM; Raymond LA
Prog Neurobiol; 2007 Apr; 81(5-6):272-93. PubMed ID: 17188796
[TBL] [Abstract][Full Text] [Related]
10. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
[TBL] [Abstract][Full Text] [Related]
11. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.
Blázquez C; Chiarlone A; Sagredo O; Aguado T; Pazos MR; Resel E; Palazuelos J; Julien B; Salazar M; Börner C; Benito C; Carrasco C; Diez-Zaera M; Paoletti P; Díaz-Hernández M; Ruiz C; Sendtner M; Lucas JJ; de Yébenes JG; Marsicano G; Monory K; Lutz B; Romero J; Alberch J; Ginés S; Kraus J; Fernández-Ruiz J; Galve-Roperh I; Guzmán M
Brain; 2011 Jan; 134(Pt 1):119-36. PubMed ID: 20929960
[TBL] [Abstract][Full Text] [Related]
12. Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons.
Rudinskiy N; Kaneko YA; Beesen AA; Gokce O; Régulier E; Déglon N; Luthi-Carter R
J Neurochem; 2009 Oct; 111(2):460-72. PubMed ID: 19686238
[TBL] [Abstract][Full Text] [Related]
13. P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases.
Takenouchi T; Sekiyama K; Sekigawa A; Fujita M; Waragai M; Sugama S; Iwamaru Y; Kitani H; Hashimoto M
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):91-6. PubMed ID: 20143170
[TBL] [Abstract][Full Text] [Related]
14. Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury.
Peng W; Cotrina ML; Han X; Yu H; Bekar L; Blum L; Takano T; Tian GF; Goldman SA; Nedergaard M
Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12489-93. PubMed ID: 19666625
[TBL] [Abstract][Full Text] [Related]
15. Functional decreases in P2X7 receptors are associated with retinoic acid-induced neuronal differentiation of Neuro-2a neuroblastoma cells.
Wu PY; Lin YC; Chang CL; Lu HT; Chin CH; Hsu TT; Chu D; Sun SH
Cell Signal; 2009 Jun; 21(6):881-91. PubMed ID: 19385050
[TBL] [Abstract][Full Text] [Related]
16. Selective neuronal degeneration in Huntington's disease.
Cowan CM; Raymond LA
Curr Top Dev Biol; 2006; 75():25-71. PubMed ID: 16984809
[TBL] [Abstract][Full Text] [Related]
17. Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease.
Ribeiro FM; Devries RA; Hamilton A; Guimaraes IM; Cregan SP; Pires RG; Ferguson SS
Hum Mol Genet; 2014 Apr; 23(8):2030-42. PubMed ID: 24282028
[TBL] [Abstract][Full Text] [Related]
18. Nortriptyline delays disease onset in models of chronic neurodegeneration.
Wang H; Guan Y; Wang X; Smith K; Cormier K; Zhu S; Stavrovskaya IG; Huo C; Ferrante RJ; Kristal BS; Friedlander RM
Eur J Neurosci; 2007 Aug; 26(3):633-41. PubMed ID: 17686041
[TBL] [Abstract][Full Text] [Related]
19. The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis.
Carmo MR; Menezes AP; Nunes AC; Pliássova A; Rolo AP; Palmeira CM; Cunha RA; Canas PM; Andrade GM
Neuropharmacology; 2014 Jun; 81():142-52. PubMed ID: 24508709
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.
Vamos E; Voros K; Vecsei L; Klivenyi P
Biomed Pharmacother; 2010 Apr; 64(4):282-6. PubMed ID: 19932584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
